Pembrolizumab biosimilar(BioGenomics )

帕博利珠单抗生物类似药（BioGenomics ）

Report date: 2025/02/20 10:08:16

Base Information

Drug NamePembrolizumab biosimilar(BioGenomics )
Drug Alias NameKeytruda biosimilar
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiogenomics
China Registration ClassN/A

Develop Information

Active CompaniesBiogenomics
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A